Uncomfortable Truths About Data, Justice, and Idiopathic Pulmonary Fibrosis in the Veterans Health Administration
Abstract
No abstract availableFunding Information
- National Institutes of Health (5T32HL105321)
This publication has 11 references indexed in Scilit:
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice GuidelineAmerican Journal of Respiratory and Critical Care Medicine, 2022
- A Policy Prescription for Reducing Health Disparities—Achieving PharmacoequityJAMA, 2021
- Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary FibrosisChest, 2021
- Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary FibrosisAnnals of the American Thoracic Society, 2021
- Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic reviewEuropean Respiratory Review, 2020
- Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment InitiationAnnals of the American Thoracic Society, 2019
- Clarifying the diagnosis of post-inflammatory pulmonary fibrosis: a population-based studyEuropean Respiratory Journal, 2019
- Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trialsBMJ Open Respiratory Research, 2018
- Code-based Diagnostic Algorithms for Idiopathic Pulmonary Fibrosis. Case Validation and ImprovementAnnals of the American Thoracic Society, 2017
- Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and NintedanibNew England Journal of Medicine, 2015